Welcome to our dedicated page for Tecogen SEC filings (Ticker: TGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Tecogen鈥檚 disclosures usually means wading through technical CHP diagrams and detailed emissions data. Investors want the revenue split between product sales and long-term service, or need to confirm when executives file Form 4 insider transactions before major project wins. This page maps every SEC release to the exact question you are asking鈥攚hether it鈥檚 backlog growth or R&D spending鈥攕o you no longer have to hunt through dense footnotes.
Type a phrase like 鈥淭ecogen quarterly earnings report 10-Q filing鈥� or 鈥淭ecogen proxy statement executive compensation鈥� and Stock Titan returns the document plus an AI-powered summary that highlights segment margins, new clean-energy incentives, and board pay packages. AG真人官方-time alerts push Tecogen Form 4 insider transactions the moment they hit EDGAR, letting you track executive stock moves without refreshing your browser. Need context? Our expert engine links related 8-Ks, turning 鈥淭ecogen 8-K material events explained鈥� into a concise timeline of project awards, financing rounds, or patent milestones.
Because Tecogen鈥檚 business blends equipment sales with recurring service revenue, understanding cash-flow nuances is critical. Our coverage spans every form鈥攆rom the 鈥淭ecogen annual report 10-K simplified鈥� that dissects backlog trends, to bite-size analytics for each 鈥淭ecogen earnings report filing analysis.鈥� Use AI plain-language explanations to compare quarter-over-quarter growth, monitor compliance with clean-air regulations, and flag subsidy disclosures. In short, this hub is your fastest route to understanding Tecogen SEC documents with AI鈥攁ll filings, all the time, always current.
Tecogen Inc. reported consolidated revenues of $14.57 million for the six months ended June 30, 2025, up from $10.91 million a year earlier, driven by a large increase in Products revenue to $5.69 million (prior $1.61 million) while Services remained roughly steady at $8.21 million and Energy Production declined to $0.67 million.
Gross profit rose to $5.68 million and consolidated net loss improved to $2.13 million for the six months (loss attributable to Tecogen $2.12 million, $(0.08) per share basic), compared with larger losses a year earlier. Cash and cash equivalents declined to $1.64 million from $5.41 million at year-end and operating activities used $3.78 million of cash in the first half. Acquisition-related contingent consideration and related liabilities tied to the Aegis maintenance acquisition carry a fair-value liability of about $1.25 million. Subsequent to the period, the company completed a public offering raising approximately $18.16 million net proceeds to fund growth and working capital.
Tecogen Inc. furnished earnings materials related to the three- and six-month periods ended June 30, 2025. The company issued a press release containing earnings commentary and supplemental information, and it has attached that press release as Exhibit 99.1 to this Current Report. Separately, Tecogen is furnishing an investor slide deck to be presented online in connection with an earnings conference call; that deck is attached as Exhibit 99.2.
The filing clarifies these items are being furnished (not "filed") for purposes of the Exchange Act. The 8-K itself does not include detailed financial figures; interested parties should review Exhibits 99.1 and 99.2 for the underlying earnings metrics and commentary.
Form 4 snapshot: On 07/24/2025 Tecogen Inc. (TGEN) granted Director John M. Albertine 25,000 stock options at an exercise price of $8.35. The options vest 25 % per year, first exercisable 07/24/2026 and expiring 07/24/2035.
The award lifts Albertine鈥檚 directly held derivative position to 175,000 options. No purchases or sales of common shares were reported and no change was disclosed in non-derivative share ownership. The filing, signed 07/28/2025, appears to be a routine board compensation grant with no immediate cash flow or share-count impact.
SEC Form 4: On 07/28/2025 Tecogen (TGEN) disclosed that its General Counsel & Secretary, John K. Whiting IV, received new equity on 07/24/2025.
- Restricted stock award: 11,976 common shares granted at $0; Whiting鈥檚 direct common share holdings rise to 12,612.
- Stock options: 24,075 options with a $8.35 strike, vesting 25 % per year beginning 07/24/2026 and expiring 07/24/2035. Total option holdings increase to 424,075.
No shares were sold. The grants increase insider alignment but introduce a modest future dilution overhang of up to 24,075 shares if exercised.
Tecogen Inc. (TGEN) Form 4 filing: Chief Accounting Officer Roger P. Deschenes reported new equity awards dated 07/24/2025.
- Restricted stock: 17,964 common shares awarded at $0 cost; direct holdings rise to 42,962 shares.
- Stock options: 12,063 options granted with a $8.35 exercise price, expiring 07/24/2035; option balance increases to 152,063.
The awards vest 25% annually, providing long-term retention incentives and aligning the CAO鈥檚 interests with shareholders. No shares were sold or disposed of.
Form 4 鈥� Tecogen Inc. (TGEN)
- Reporting person: Susan B. Hirsch, Director.
- Transaction date: 07/24/2025.
- Instrument: Stock Option (right to buy) covering 25,000 common shares at an exercise price of $8.35.
- Vesting: 25 % per year; first exercisable 07/24/2026; expiration 07/24/2035.
- Post-transaction holdings: Hirsch now directly holds 150,000 derivative securities (options).
No non-derivative (common stock) transactions were reported. The filing reflects a routine option grant to a board member and does not disclose cash compensation, sale activity, or changes in direct share ownership.
Form 4 filing for Tecogen Inc. (TGEN) discloses that director Ahmed Ghoniem received a new equity award on 24 Jul 2025.
- Security: Non-qualified stock option granting the right to purchase 25,000 common shares.
- Exercise price: $8.35 per share.
- Vesting: 25 % annually (fully vested after four years, per footnote 1).
- Expiration: 24 Jul 2035, giving a 10-year term after the first vesting date.
- Post-grant holdings: Filing shows 237,723 derivative securities held directly (includes the new option).
- Role: Ghoniem is marked as a Director; no change in status or control is indicated.
The transaction is classified under code 鈥淎鈥� (grant) and represents routine director compensation rather than an open-market purchase or sale. No non-derivative share activity or cash proceeds are reported, and no other executives are listed. Financial performance metrics, earnings data, or guidance are not included in this filing.
Form 4 filing synopsis: Tecogen Inc. (TGEN) director Earl R. Lewis was granted 25,000 non-qualified stock options on 07/24/2025 at an exercise price of $8.35 per share. The award vests 25 % each year and carries a 10-year term, expiring 07/24/2035. No common shares were bought or sold and no cash changed hands at the time of grant.
After this transaction, Lewis holds 91,250 derivative securities (options) in total, all recorded as direct ownership. The filing represents routine equity compensation aimed at aligning the director鈥檚 incentives with long-term shareholder value. Because the transaction involves options rather than immediate share issuance, near-term cash flow and ownership percentages are unaffected; any dilution would occur only if the options are exercised in the future.
FAQ
What is the current stock price of Tecogen (TGEN)?
What is the market cap of Tecogen (TGEN)?
